Notify me when BENNICAS & ASSOCIATES, INC. files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2022 | 97 | $173,003,693 | +$4,795,755 | -$7,101,782 | -$2,306,027 | PG, STPZ, SH, NEM, ABBV | Restatement | 28 Feb 2023, 18:30 |
| Q3 2022 | 96 | $156,834,000 | +$2,732,105 | -$2,042,372 | +$689,733 | PG, STPZ, SH, NEM, ABBV | 13F-HR | 13 Oct 2022, 12:50 |
| Q2 2022 | 99 | $171,313,000 | +$1,133,997 | -$6,817,720 | -$5,683,723 | PG, STPZ, NEM, ABBV, SH | 13F-HR | 12 Jul 2022, 13:33 |
| Q1 2022 | 106 | $199,131,000 | +$8,872,726 | -$6,481,977 | +$2,390,749 | PG, STPZ, NEM, ABBV, FNV | 13F-HR | 14 Apr 2022, 18:34 |
| Q4 2021 | 101 | $192,245,000 | +$8,118,649 | -$5,738,120 | +$2,380,529 | PG, STPZ, NEM, ABBV, MSFT | 13F-HR | 14 Jan 2022, 15:28 |
| Q3 2021 | 99 | $177,728,000 | +$5,739,552 | -$4,678,927 | +$1,060,625 | PG, STPZ, NEM, MSFT, ABBV | 13F-HR | 08 Oct 2021, 14:07 |
| Q2 2021 | 99 | $181,758,000 | +$4,363,705 | -$842,357 | +$3,521,348 | PG, STPZ, NEM, MSFT, ABBV | 13F-HR | 09 Jul 2021, 15:52 |
| Q1 2021 | 99 | $174,221,000 | +$4,659,431 | -$3,537,869 | +$1,121,562 | PG, STPZ, NEM, MSFT, ABBV | 13F-HR | 14 Apr 2021, 19:47 |
| Q4 2020 | 99 | $171,581,000 | +$11,703,951 | -$8,442,565 | +$3,261,386 | PG, STPZ, NEM, CEF, ABBV | 13F-HR | 15 Jan 2021, 12:55 |
| Q3 2020 | 94 | $160,933,000 | +$24,697,660 | -$3,457,894 | +$21,239,766 | PG, STPZ, NEM, SH, CEF | 13F-HR | 14 Oct 2020, 17:46 |
| Q2 2020 | 82 | $133,241,000 | +$1,776,831 | -$1,821,874 | -$45,043 | PG, NEM, MSFT, SH, ABBV | 13F-HR | 14 Jul 2020, 16:22 |
| Q1 2020 | 78 | $113,215,000 | +$4,928,922 | -$7,220,498 | -$2,291,576 | PG, SH, MSFT, NEM, CEF | 13F-HR | 14 Apr 2020, 18:50 |
| Q4 2019 | 85 | $138,302,000 | +$8,350,562 | -$7,158,528 | +$1,192,034 | PG, MSFT, NEM, ABBV, Merck & Co. | 13F-HR | 16 Jan 2020, 17:35 |
| Q3 2019 | 83 | $129,108,000 | +$3,944,398 | -$364,516 | +$3,579,882 | PG, MSFT, NEM, ABBV, Merck & Co. | 13F-HR | 07 Oct 2019, 16:31 |
| Q2 2019 | 83 | $119,890,000 | +$2,895,412 | -$2,511,386 | +$384,026 | PG, MSFT, NEM, Merck & Co., CSX | 13F-HR | 12 Jul 2019, 13:37 |
| Q1 2019 | 82 | $113,846,000 | +$246,021 | -$4,977,013 | -$4,730,992 | PG, MSFT, Merck & Co., CSX, NEM | 13F-HR | 15 Apr 2019, 19:18 |
| Q4 2018 | 87 | $108,616,000 | +$2,724,030 | -$5,318,604 | -$2,594,574 | PG, MSFT, Merck & Co., NEM, CEF | 13F-HR | 18 Jan 2019, 13:26 |
| Q3 2018 | 93 | $115,300,000 | +$783,635 | -$290,469 | +$493,166 | PG, MSFT, CSX, Merck & Co., CLX | 13F-HR | 17 Oct 2018, 15:28 |
| Q2 2018 | 90 | $112,546,000 | +$2,219,888 | -$3,291,220 | -$1,071,332 | PG, MSFT, NEM, CSX, CEF | 13F-HR | 20 Jul 2018, 15:19 |
| Q1 2018 | 90 | $111,983,000 | +$12,058,966 | -$10,646,000 | +$1,412,966 | PG, MSFT, NEM, CEF, CSX | 13F-HR | 19 Apr 2018, 18:49 |
| Q4 2017 | 85 | $114,778,000 | +$1,118,566 | -$7,105,330 | -$5,986,764 | PG, MSFT, NEM, INTC, CEF | 13F-HR | 23 Jan 2018, 19:20 |
| Q3 2017 | 89 | $117,494,000 | +$5,086,008 | -$3,554,383 | +$1,531,625 | PG, MSFT, CSX, NEM, Merck & Co. | 13F-HR | 25 Oct 2017, 17:05 |
| Q2 2017 | 89 | $111,601,000 | +$936,209 | -$790,702 | +$145,507 | PG, CSX, MSFT, Merck & Co., CLX | 13F-HR | 19 Jul 2017, 14:44 |
| Q1 2017 | 88 | $112,047,000 | +$275,781 | -$5,005,002 | -$4,729,221 | PG, CSX, Merck & Co., MSFT, CLX | 13F-HR | 17 Apr 2017, 19:31 |
| Q4 2016 | 88 | $110,588,000 | +$5,469,142 | -$1,423,918 | +$4,045,224 | PG, MSFT, Merck & Co., NEM, UnitedHealth Group Inc. | 13F-HR | 19 Jan 2017, 15:18 |
| Q3 2016 | 84 | $109,881,000 | +$2,072,810 | -$4,075,939 | -$2,003,129 | PG, Merck & Co., NEM, CEF, MSFT | 13F-HR | 17 Oct 2016, 14:57 |
| Q2 2016 | 85 | $111,298,000 | +$1,561,761 | -$3,894,300 | -$2,332,539 | PG, CLX, NEM, CEF, Merck & Co. | 13F-HR | 18 Jul 2016, 19:14 |
| Q1 2016 | 86 | $105,096,000 | +$1,959,064 | -$6,763,675 | -$4,804,611 | PG, CLX, MSFT, Merck & Co., CEF | 13F-HR | 18 Apr 2016, 15:19 |
| Q4 2015 | 86 | $103,497,000 | +$2,191,146 | -$11,618,517 | -$9,427,371 | PG, CLX, MSFT, Merck & Co., INTC | 13F-HR | 28 Jan 2016, 19:30 |
| Q3 2015 | 86 | $107,316,000 | +$4,068,000 | -$8,481,465 | -$4,413,465 | PG, CLX, SH, Merck & Co., CEF | 13F-HR | 27 Oct 2015, 17:59 |
| Q2 2015 | 87 | $122,124,000 | +$7,142,742 | -$1,448,696 | +$5,694,046 | PG, CLX, Merck & Co., CEF, CSX | 13F-HR | 17 Jul 2015, 14:25 |
| Q1 2015 | 88 | $119,198,000 | +$3,760,334 | -$7,353,558 | -$3,593,224 | PG, Merck & Co., CLX, CEF, CSX | 13F-HR | 17 Apr 2015, 14:59 |
| Q4 2014 | 15 | $17,432,000 | $0 | $0 | $0 | CEF, GG, PHYS, SLW, NEM | New Holdings | 15 Apr 2015, 18:11 |
| Q4 2014 | 87 | $125,518,000 | +$6,948,409 | -$4,337,848 | +$2,610,561 | PG, Merck & Co., CSX, INTC, CLX | 13F-HR | 03 Feb 2015, 13:31 |
| Q3 2014 | 80 | $121,580,000 | +$28,466 | -$1,644,387 | -$1,615,921 | PG, Merck & Co., INTC, CSX, CLX | 13F-HR | 14 Oct 2014, 16:03 |
| Q2 2014 | 82 | $127,967,000 | +$6,958,245 | -$8,340,410 | -$1,382,165 | PG, Merck & Co., CEF, GG, CVX | 13F-HR | 14 Jul 2014, 18:33 |
| Q1 2014 | 82 | $125,199,000 | +$197,470 | -$9,875,146 | -$9,677,676 | PG, Merck & Co., CEF, CSX, GG | 13F-HR | 24 Apr 2014, 18:17 |
| Q4 2013 | 86 | $130,995,000 | $0 | $0 | $0 | PG, Merck & Co., CVX, CEF, CLX | 13F-HR | 10 Feb 2014, 14:31 |